Pharma Mar (OTCMKTS:PHMMF) Reaches New 12-Month Low – What’s Next?

Pharma Mar (OTCMKTS:PHMMF) reached a new 52-week low during mid-day trading on Friday . The stock traded as low as $79.00 and last traded at $79.00, with a volume of 100 shares. The stock had previously closed at $100.60.

Analyst Upgrades and Downgrades

Separately, BTIG Research assumed coverage on Pharma Mar in a research note on Thursday, April 23rd. They issued a “buy” rating on the stock. One investment analyst has rated the stock with a Buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy”.

Pharma Mar Trading Down 21.0%

The company has a quick ratio of 2.44, a current ratio of 3.02 and a debt-to-equity ratio of 0.14. The company has a 50 day moving average of $105.26 and a 200-day moving average of $94.59.

Pharma Mar Company Profile

PharmaMar is a Spain-based biopharmaceutical company that specializes in the discovery and development of novel oncology therapies derived from marine organisms. Founded in 1986 as part of Grupo Zeltia, the company has pioneered the use of compounds extracted from deep-sea organisms to create synthetic analogs aimed at treating various forms of cancer. Its core expertise lies in marine biotechnology, medicinal chemistry and oncology-focused clinical development.

The company’s flagship product is Yondelis (trabectedin), an antitumor agent approved in the European Union for the treatment of soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer.